The light-hearted debate, “Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists: Are We Ready for Prime Time?” took place Monday during the 80th American Diabetes ...

Please provide your email address to receive an email when new articles are posted on . Most of the studies compared TNF inhibitors with non-TNF-inhibitor DMARDs. The results may indicate that ...

A common class of drugs called anticholinergics might boost risks for heart failure and other dangerous cardiac conditions, a ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on her recent paper that takes a closer look at the regulatory treatments for ...